Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive ...

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for ...

This follows the exclusive Commercialization and Distribution Agreement entered into with Nippon Shinyaku in the United States in January 2022.

Capricor Therapeutics Signs Binding Term Sheet with Nippon ...

“Our expanded partnership with Nippon Shinyaku into the European region marks ... Capricor has entered into an agreement for the exclusive ...

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for ...

Capricor Therapeutics and Nippon Shinyaku enter partnership for exclusive commercialization and distribution of CAP-1002 for the treatment of Duchenne muscular ...

Nippon Shinyaku and Capricor Therapeutics enter into an Exclusive ...

Nippon Shinyaku and Capricor Therapeutics enter into an Exclusive Partnership for. Commercialization and Distribution of CAP-1002 for the ...

Capricor Therapeutics Signs Binding Term Sheet with Nippon

Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan.

Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive ...

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon ...

September 18, 2024 Nippon Shinyaku and Capricor Therapeutics ...

the U.S. Nippon Shinyaku has entered into an exclusive distribution agreement for CAP-1002 for the U.S. and Japan in January 2022 and ...

Capricor Therapeutics and Nippon Shinyaku Enter Partnership

Capricor Therapeutics and Nippon Shinyaku enter partnership for exclusive commercialization and distribution of CAP-1002 for the treatment of Duchenne muscular ...

Capricor and Nippon Shinyaku partner for DMD therapy distribution

Capricor Therapeutics and Nippon Shinyaku have entered a collaboration for exclusively commercialising and distributing the CAP-1002.

Capricor and Nippon Shinyaku Partner to Commercialize and ...

Capricor Therapeutics entered into a partnership with Nippon Shinyaku for the exclusive commercialization and distribution in Japan of ...

Capricor Therapeutics Signs Binding Term Sheet with Nippon ...

Capricor Therapeutics (NASDAQ: CAPR) has entered a binding term sheet with Nippon Shinyaku for the commercialization and distribution of deramiocel in Europe.

NS Pharma Shares Community Letter Announcing Partnership With ...

We are excited to share the news that our parent company, Nippon Shinyaku, has entered into an exclusive partnership with Capricor Therapeutics for the ...

Capricor Therapeutics Announces Proposed Public Offering of ...

Capricor has entered into an agreement for the exclusive ... in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. ...

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for ...

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular ...

NEWS 2023 - Press Releases NIPPON SHINYAKU CO., LTD.

... the treatment of iron deficiency anemia. February 16, 2023 R & D PDF244 KB. Nippon Shinyaku and Capricor Therapeutics enter into an Exclusive Partnership for ...

Capricor Therapeutics Announces Intent to File Biologics License ...

Capricor has entered into an agreement for the exclusive ... in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. ...

Press Releases - NS Pharma

November 13, 2024. Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive Strategic Collaboration for ATSN-101 in the U.S. and Japan.

Capricor Therapeutics

... Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular ...

Strategic Partnerships - NS Pharma, Inc. - Capricor Therapeutics

Nippon Shinyaku, Co., Ltd. (U.S. Subsidiary: NS Pharma, Inc.) Capricor has entered into Exclusive Commercialization and Distribution Agreements with Nippon ...

Nippon Shinyaku's R&D Activities

... 1000mg for the treatment of iron deficiency anemia. February 16, 2023: Nippon Shinyaku and Capricor Therapeutics enter into an Exclusive Partnership for ...